drugset / Trial / NCT05622864

Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients

NCT05622864

Phase 1 Completed 106 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

The increased safety and tolerance of single and multiple atomized inhalation of HRS-9821 suspension for inhalation doses in healthy subjects and COPD patients.

Timeline

Start
2023-01-12
Primary completion
2025-05-07
Completion
2025-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9821 Unknown Inhaled